Geographic Atrophy secondary to Age Related Macular Degeneration Clinical Trials

8 recruitingLast updated: June 18, 2026

There are 8 actively recruiting geographic atrophy secondary to age related macular degeneration clinical trials across 15 countries. Studies span Phase 2, Not Applicable, Phase 1. Top locations include Dallas, Texas, United States, Ottawa, Ontario, Canada, Carmel, Indiana, United States. Updated daily from ClinicalTrials.gov.


Geographic Atrophy secondary to Age Related Macular Degeneration Trials at a Glance

8 actively recruiting trials for geographic atrophy secondary to age related macular degeneration are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Dallas, Ottawa, and Carmel. Lead sponsors running geographic atrophy secondary to age related macular degeneration studies include Complement Therapeutics, Apellis Pharmaceuticals, Inc., and ADARx Pharmaceuticals, Inc..

Browse geographic atrophy secondary to age related macular degeneration trials by phase

About Geographic Atrophy secondary to Age Related Macular Degeneration Clinical Trials

Looking for clinical trials for Geographic Atrophy secondary to Age Related Macular Degeneration? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Geographic Atrophy secondary to Age Related Macular Degeneration trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Geographic Atrophy secondary to Age Related Macular Degeneration clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

Geographic Atrophy secondary to Age Related Macular Degeneration
Complement Therapeutics75 enrolled12 locationsNCT07144137
Recruiting
Phase 2

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Geographic Atrophy secondary to Age Related Macular Degeneration
Novartis Pharmaceuticals272 enrolled28 locationsNCT07441642
Recruiting
Phase 2

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

Geographic Atrophy secondary to Age Related Macular Degeneration
Apellis Pharmaceuticals, Inc.240 enrolled68 locationsNCT07215390
Recruiting
Not Applicable

Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy

Geographic Atrophy secondary to Age Related Macular Degeneration
Okuvision GmbH70 enrolled5 locationsNCT07531927
Recruiting
Phase 1Phase 2

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

Geographic Atrophy secondary to Age Related Macular Degeneration
Complement Therapeutics75 enrolled4 locationsNCT07392255
Recruiting
Not Applicable

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

Geographic Atrophy secondary to Age Related Macular DegenerationAge-Related Macular DegenerationIntermediate AMD+1 more
i-Lumen Scientific AUS PTY LTD100 enrolled13 locationsNCT06662162
Recruiting
Phase 1Phase 2

A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

Geographic Atrophy secondary to Age Related Macular Degeneration
Kriya Therapeutics, Inc.62 enrolled3 locationsNCT06765980
Recruiting
Phase 2

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

Geographic Atrophy secondary to Age Related Macular Degeneration
ADARx Pharmaceuticals, Inc.240 enrolled24 locationsNCT06990269